Centessa licenses LockBody platform to Genmab; $15M upfront, up to $230M per product milestones

Centessa Pharmaceuticals plc

Upfront payment of $15M from Genmab; option fees up to $15M for up to three undisclosed targets.
Eligible for ~$230M in development, regulatory, and sales milestones per product plus tiered mid-single-digit royalties.
Genmab to lead all R&D; may combine LockBody technology with Genmab's proprietary antibodies.
LockBody platform enables conditional activation of cell killing in diseased tissue to improve therapeutic index.
Multi-year research period; Genmab can terminate for convenience or on a target-by-target basis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.